Nurses & Pharmacists Session

Agenda

Friday September 12, 2014 - Low Risk MDS

7:00 am - 8:00 am
8:00 am - 8:30 am

8:30 am – 9:00 am

9:00 am – 9:30 am
9:30 am – 9:50 am
9:50 am - 10:15 am

10:15 am - 10:50 am
10:50 am - 11:20 am
11:20 am - 12:00 pm
12:00 pm - 1:00 pm
12:00 pm - 1:00 pm
1:00 pm - 1:30 pm

1:30 pm - 2:00 pm
2:00 pm - 2:30 pm

2:30 pm - 2:45 pm
2:45 pm - 3:15 pm

6:00 pm - 8:00 pm

 

Breakfast
Prognostication MDS Including What's New in the WHO -  Dr. John Bennett

Spectrum of Molecular Aberrations in MDS
- Dr. Benjamin Ebert
Spliceosome Mutations in MDS - Dr. Tim Graubert
Break and Visit with the Sponsors
Platelet Transfusion Strategies in Myelodysplastic Syndromes- Dr. Dawn Sheppard

Lenalidomide Role in MDS
 - Dr. Alan List
Applying Lessons Learned in Iron Management to MDS -  Dr. John Porter
Does Iron Impact the Natural History of MDS? -  Dr. Norbert Gattermann
Lunch with the Experts
Resident Morphology Session / Lunch - Dr. John Bennett
Prognosis & Treatment of CMML & Other Overlap Syndromes - Dr. David Steensma
Implications of PNH Clones in MDS
- Dr. Richard Wells
The Impact of Patient Related Factors on Clinical and Patient Reported Outcomes in MDS- Dr. Rena Buckstein
Abstract Presentation:Winner of Young Investigator Award: Alyssa Cull
The Mechanism of Lenalidomide Activity - Dr. Benjamin Ebert

Welcome Reception - Sponsored by AAMAC


Saturday September 13, 2014 - High Risk MDS

7:00 am - 8:00 am
8:00 am - 12:00 pm
8:00 am - 8:30 am
8:30 am - 9:00 am
9:00 am - 9:30 am

9:30 am - 10:00 am
10:00 am - 10:30 am
10:30 am - 11:00 am
11:00 am - 11:30 am

11:30 am - 12:00 pm
12:00 pm - 1:00 pm
1:00 pm - 1:30 pm
1:30 pm - 2:15pm

2:15 pm - 3:00 pm

Breakfast
Nurses and Pharmacists Session
When to Transplant in MDS- Dr. Corey Cutler
Predictors of Clinical Response to Hypomethylating Agents
- Dr. Pierre Fenaux
What to do with Hypomethylating Agent Failures? Up and Coming Therapies in AML & MDS- Dr. Mikkael Sekeres
Clearpath
- Drs. Wells, Leitch, Olney & Shamy

Break

Transplant Strategies and Regimens in MDS- Dr. Corey Cutler
Optimal Therapy for Therapy-Related AML- Low and High Blast Counts- Dr. Pierre Fenaux 
Impact of the Bone Marrow Microenvironment in MDS- Dr. Aly Karsan
Lunch with the Experts
MDS Landscape in Canada- Dr. Nancy Zhu
What will MDS Care Look Like in 5 Years- Dr. Mikkael Sekeres and Dr. David Steensma

Cases Panel Discussion
- Chair Dr. Heather Leitch, Panel: Drs. Savoie, Storring & Zhu